Kansagra, Ankit J.; Frey, Noelle V.; Bar, Merav; Laetsch, Theodore Willis; Carpenter, Paul A.; Savani, Bipin N.; Heslop, Helen E.; Bollard, Catherine M.; Komanduri, Krishna V.; Gastineau, Dennis A.; Chabannon, Christian; Perales, Miguel Ángel; Hudecek, Michael; Aljurf, Mahmoud Deeb; Andritsos, Leslie A.; Barrett, John A.; Bachanova, V.; Bonini, Chiara; Ghobadi, Armin; Gill, Saar I.; Hill, Joshua A.; Kenderian, Saad Sirop Irop; Kebriaei, Partow; Nagler, Arnon; Maloney, David G.; Liu, Hien D.; Shah, Nirali N.; Kharfan-Dabaja, M. A.; Shpall, Elizabeth J.; Mufti, Ghulam J.; Johnston, Laura J.; Jacoby, Elad; Bazarbachi, Ali Abdul Hamid; DIpersio, John F.; Pavletic, Zivko Steven; Porter, David L.; Grupp, Stephan A.; Sadelain, Michel W.J.; Litzow, Mark Robert; Mohty, Mohamad; Hashmi, Shahrukh Khurshid
(Nature Publishing Group, 2019)
On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), ...